Adagio discloses additional compensation for Interim CEO Hering: $510K base, $7.5K monthly stipend

Invivyd, Inc.

David Hering appointed Interim CEO on Feb 23, 2022 after Tillman Gerngross resigned as CEO and board member.
Compensation approved Mar 18: base salary increased to $510,000 (eff. Feb 23) plus $7,500 monthly stipend during interim role.
2022 target bonus uses blended rate: 60% at assumed $600K salary for Interim CEO time, 40% at $410K for COO time.
Tom Heyman reclassified from Class II to Class III director to rebalance board classes following Gerngross resignation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

David Hering

Interim Chief Executive Officer

IVVD · Invivyd, Inc.

Effective: 2022-02-23
Filed: March 21, 2022, 7:59 PM ET

Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.

Departed

Tillman U. Gerngross

Chief Executive Officer and President

IVVD · Invivyd, Inc.

Effective: 2022-02-23
Successor: David Hering
Filed: March 21, 2022, 7:59 PM ET

On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..

Action: resigned
Role: Chief Executive Officer and President

Exact text from the filing

On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-079997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.